NBIX
Neurocrine Biosciences, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website neurocrine.com
- Employees(FY) 1400
- ISIN US64125C1099
Performance
+1.88%
1W
+6.99%
1M
+7.54%
3M
+30.82%
6M
+7.99%
YTD
+49.35%
1Y
Profile
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Investment Analysis Report: NBIX
Overview
In this investment analysis report, we will delve into the financial statements of NBIX, a company in the Health Technology sector specializing in Pharmaceuticals. We will analyze the Balance Sheets, Income Statements, and Cashflow Statements to gain insights into the company's financial health, growth p...
Technical Analysis of NBIX 2024-05-10
Overview:
In analyzing the technical indicators for NBIX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide investment ...
Recent News & Updates
- 2024-05-01 08:31
- 2024-05-01 08:15
- 2024-05-01 07:18
Neurocrine: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-01 07:00
- 2024-04-30 23:54
- 2024-04-30 21:30
- 2024-04-30 20:15
- 2024-04-30 19:00
- 2024-04-30 17:48
- 2024-04-30 17:45
- 2024-04-30 17:31
- 2024-04-30 17:12
- 2024-04-30 09:15
- 2024-04-30 05:12
- 2024-04-29 21:15
- 2024-04-24 10:01
- 2024-04-24 08:30
- 2024-04-24 08:00
3 Red-Hot Biotech Rockets Blasting Off in 2024(InvestorPlace)
- 2024-04-23 22:01
- 2024-04-23 20:30
- 2024-04-23 20:00
NBIX: Raising target price to $147.00(Argus Research)
- 2024-04-23 16:02
Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?(Investor's Business Daily)
- 2024-04-23 11:50
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win(Investor's Business Daily)
- 2024-04-23 07:22
Neurocrine scores surprise win with depression drug(BioPharma Dive)
- 2024-04-23 07:00
- 2024-04-22 19:00
- 2024-04-22 11:10
10 Best Performing Biotech ETFs in 2024(Insider Monkey)
- 2024-04-21 23:10
10 Best Performing Biotech ETFs in 2024(Insidermonkey)
- 2024-04-16 16:01
- 2024-04-16 04:01